|
||||||
Recent Issues2010Spring Summer 2009 April June August October/November Winter 2009–2010 2008 May/June July/August September/October November/December 2007 February April June August October December 2006 February April June August October December 2005 February April June August October December 2004 March May July/August September October December About Biotechnology Healthcare JournalRate CardProduction Specifications Call for Papers Conflict-of-interest form (PDF) Writers’ Guidelines Masthead Editorial Board Subscriptions Reprints |
October 2004FeaturesLeading Edge Moving Away From Injectables: Pills, Patches, and Pulmonary PathwaysSome biotech companies are devoting sizeable resources to finding more mainstream forms of drug delivery, including oral, transdermal, inhaled, and ocular administration. P&T committees, watch closely: Easier dosing could bring broader acceptance. Policy Essays by Bush, Kerry on Funding Stem-Cell ResearchThe presidential candidates express their views for Biotechnology Healthcare on that high-voltage crossing of science and societal values: federal funding for stem-cell research. Specialty Pharmacy Taking Action in Tennessee: How This Blues Affiliate Manages CostsLike many insurers, Blue Cross/Blue Shield of Tennessee feels the pain of soaring specialty drug expenses. Jane Havens, RN, was told to “Do something about it.” Her team developed innovative approaches to managing injectables – but only after it learned the extreme complexity of the situation. Clinical Surrogate Markers of Efficacy for Drug Treatment of Viral HepatitisWaiting for signs of disease progression is impractical when sizing up the effectiveness of therapy for hepatitis B and C. Timothy M. Block, PhD, and W. Thomas London, MD, discuss alternate means of evaluation. Regulatory Scandal Brewing Over Drug Trial RegistryPoliticians posture while jittery journal editors excoriate manufacturers for locking less-than-favorable clinical trial data away in a file drawer. The situation is complicated enough, thank you, without Washington’s “help.” DepartmentsOpeners Stuff of science ... or fiction?
Michael D. Dalzell Editorial CRR of the IOMDavid B. Nash, MD, MBA, on the CRR. Drugs & Diagnostics Predicting the Forces That Will Shape Specialty PharmacySpecialty pharmacy’s future role. Also, approvals, denials, and clinical trials. Biotech Business Greenwood: Affordability, Reimportation, Stem Cell Among Biotech’s Big ChallengesRep. James Greenwood, taking BIO’s helm, talks with us about challenges. Discourse Is the Lynch Mob Coming for Biotech?Sirens sound over price-control talk. Corporate Spotlight Reducing the Economic and Clinical Burden of CKD in the Managed Care Setting
Samir H. Mody, PharmD, MBA In the Pipeline Biotechnology Moves Toward More Important Role in Treating Chronic Illness
Amanda Brower |
|||||